October 7, 2016
Experts of osteoporosis treatments lamented the discontinuation of development of odanacatib, which was expected to be safer and more effective than existing drugs, at the annual meeting of the Japan Osteoporosis Society (JOS). Odanacatib, a cathepsin K inhibitor, was being...read more